VUNO Med®–DeepCARS® represents a major advancement in predictive healthcare technology. Developed by VUNO, a leading medical AI company, the solution uses deep learning to forecast the risk of in-hospital cardiac arrest up to 24 hours in advance. By continuously analyzing patient vital signs—including heart rate, blood pressure, respiratory rate, and temperature—DeepCARS® delivers real-time risk scores that enable clinicians to make proactive decisions. Its AI-driven precision sets it apart from traditional early warning systems, offering an innovative approach to preventing life-threatening events before they occur.

Demonstrated at AACN NTI 2025, DeepCARS® drew the attention of critical care professionals and Rapid Response Teams (RRTs) for its practical application in hospital wards. Already implemented in over 48,000 beds across South Korea, including major tertiary hospitals, the solution has proven its value in supporting clinical workflows. Its integration into daily hospital operations provides healthcare teams with timely alerts that allow for early intervention, improving outcomes for high-risk patients without requiring additional manual input or disruption to existing routines.

With in-hospital cardiac arrest posing a persistent challenge in acute care, DeepCARS® addresses a critical gap by equipping clinicians with foresight rather than hindsight. The system not only enhances patient safety but also contributes to hospital efficiency by reducing emergency incidents and unplanned ICU transfers. As it undergoes FDA 510(k) clearance following Breakthrough Device Designation, VUNO aims to bring this life-saving technology to U.S. hospitals. DeepCARS® marks a significant step toward smarter, AI-enabled clinical care that prioritizes prevention and precision.

MedTech Spectrum's Summary

Proactive Cardiac Risk Prediction: DeepCARS® uses AI to predict in-hospital cardiac arrest up to 24 hours in advance, enabling earlier clinical intervention and potentially saving lives.

Proven Clinical Impact: Already deployed in over 48,000 hospital beds in South Korea, the system has demonstrated real-world effectiveness in improving patient safety and hospital efficiency.

Global Expansion with FDA Pathway: With FDA Breakthrough Device Designation and ongoing 510(k) clearance, VUNO is positioning DeepCARS® for adoption in U.S. hospitals, marking a major step in advancing AI-powered critical care globally.